REBLOZYL (luspatercept-aamt)
ERYTHROID (RBC) MATURATION AGENTS · ANEMIA IN BETA THALASSEMIA ·+3
CELGENE/BMS
Drug class
Erythroid (RBC) Maturation Agents
Erythroid maturation agents are a therapeutic class of recombinant fusion proteins designed to promote effective red blood cell production by overcoming blocks in terminal erythroid differentiation. Read more about Erythroid (RBC) Maturation Agents
1 drugs in this class 1 manufacturers
Drugs in Erythroid (RBC) Maturation Agents
Filter & compare in the drug finder →
Opens the drug finder with Erythroid (RBC) Maturation Agents preselected. Add indication or manufacturer filters there.
Erythroid maturation agents are a therapeutic class of recombinant fusion proteins designed to promote effective red blood cell production by overcoming blocks in terminal erythroid differentiation.
These agents, exemplified by luspatercept, function primarily as ligand traps that bind select transforming growth factor-beta superfamily ligands—such as growth differentiation factors and activins—thereby inhibiting aberrant SMAD2/3 signaling pathways that impair late-stage erythroid maturation.
Clinically, they are used to treat chronic anemia and reduce red blood cell transfusion dependence in disorders characterized by ineffective erythropoiesis, most notably lower-risk myelodysplastic syndromes and beta-thalassemia.
-
nih.gov
Erythroid maturation agents are a therapeutic class of recombinant fusion proteins designed to promote effective red blood cell production by overcoming blocks in terminal erythroid differentiation These agents, exemplified by luspatercept, function primarily as ligand traps that bind select transforming growth factor-beta superfamily ligands—such as growth differentiation factors and activins—thereby inhibiting aberrant SMAD2/3 signaling pathways that impair late-stage erythroid maturation Clin...
-
nih.gov
Erythroid maturation agents are a therapeutic class of recombinant fusion proteins designed to promote effective red blood cell production by overcoming blocks in terminal erythroid differentiation These agents, exemplified by luspatercept, function primarily as ligand traps that bind select transforming growth factor-beta superfamily ligands—such as growth differentiation factors and activins—thereby inhibiting aberrant SMAD2/3 signaling pathways that impair late-stage erythroid maturation
-
cancer.gov
Erythroid maturation agents are a therapeutic class of recombinant fusion proteins designed to promote effective red blood cell production by overcoming blocks in terminal erythroid differentiation
-
nih.gov
These agents, exemplified by luspatercept, function primarily as ligand traps that bind select transforming growth factor-beta superfamily ligands—such as growth differentiation factors and activins—thereby inhibiting aberrant SMAD2/3 signaling pathways that impair late-stage erythroid maturation
-
nih.gov
Clinically, they are used to treat chronic anemia and reduce red blood cell transfusion dependence in disorders characterized by ineffective erythropoiesis, most notably lower-risk myelodysplastic syndromes and beta-thalassemia
-
nih.gov
Clinically, they are used to treat chronic anemia and reduce red blood cell transfusion dependence in disorders characterized by ineffective erythropoiesis, most notably lower-risk myelodysplastic syndromes and beta-thalassemia
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.